Suspension and Cancellation of Device Registration in Nigeria: Six Grounds under Article 8

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Nigeria concentrates the suspension and cancellation of device registrations in Article 8, which sets out six grounds:

(a) the grounds on which the registration decision was made are false or incomplete;

(b) the conditions on which the registration was granted are contravened;

(c) non-compliance with provisions concerning quality, performance, safety or purity;

(d) the device is ineffective for the approved purpose;

(e) premises fail to comply with the relevant GMP / GDP / GWP requirements;

(f) the holder issues a written notice of intention to suspend.

Once a ground is triggered, Article 8(2) requires an order to withdraw the device from circulation and to publicise the decision. Article 8(3) then provides that resumption of placing on the market requires notification and, where the certificate has expired, payment of the renewal fee. Read together, these provisions mean that a suspension is never a private matter between the agency and the certificate holder: it is a public regulatory event with downstream effects on customers, distributors and tenders.

2. Legal basis

RegulationReference numberPublication dateProvisions
NAFDAC Medical Devices and Related Products (Registration, Labelling and Advertisement) Regulations, 2024S.I. No. 42 of 202416 October 2024Articles 8(1)–(3) (grounds for suspension and cancellation, withdrawal from circulation and publicity, resumption), Article 15 (sealing of premises), Article 48 (penalties), Article 49 (forfeiture)
NAFDAC Medical Devices GMP Guidelines 2024DER-GDL-025-00Effective 11 November 2024§11.3–§11.7 (nonconforming product, rework, CAPA)
NAFDAC Guidelines for Registration of Medical Devices (Imported and Locally Manufactured) in NigeriaR&R-GDL-008-02Effective 3 May 2024§5.0–§5.1 (GMP steps), §12.2 (5-year validity)

3. Expert insights

Insight one: Article 8(1)(a) is a retrospective ground — even errors made at application can be pursued later.

Article 8(1)(a) targets situations where the grounds on which the decision was made are false or incomplete. This means the risk exists not only in post-market conduct but also in any distortion of information at the application stage — classification rationale, manufacturer information, the content of the Certificate of Manufacture Free Sale (CMFS), label artwork, performance data. This is why we stressed the consistency of the CMFS and application information in article 16: inconsistency is not a formal defect; it is a substantive risk under Article 8(1)(a). A certificate obtained on the strength of inaccurate information is a certificate that can be taken away on the same strength.

Insight two: Article 8(1)(e) ties premises obligations directly to the certificate.

Article 8(1)(e): premises fail to comply with the relevant GMP, GDP and GWP (good manufacturing, distribution and warehousing practices) requirements. Note that these three are not limited to manufacturing sites — the warehousing and distribution premises of importers (GDP, GWP) are equally within scope. When selecting local partners, warehousing and distribution conditions are subject to audit, not merely to paper documentation. A partner whose warehouse cannot demonstrate temperature control or record-keeping is a direct threat to your certificate, not just to your logistics.

Insight three: withdrawal from circulation plus publicity under Article 8(2) carries a commercial cost far greater than the administrative one.

Article 8(2) requires NAFDAC to order withdrawal from circulation and to publicise the decision. For a brand, publicity means a public record — this affects hospital procurement eligibility, distributor confidence, and it also spills over onto other registered products of the same company. The cost of a suspension is not limited to the single certificate concerned. Reputation, tender frameworks and channel relationships all absorb the shock, and none of them can be restored by simply curing the technical non-compliance.

Insight four: the sealing power in Article 15 and the forfeiture in Article 49 are the enforcement teeth of Article 8.

Article 15: NAFDAC has the power to seal premises. Article 49: courts may order the forfeiture of proceeds and instruments. The enforcement chain formed by these provisions runs: ground identified → suspension or cancellation → withdrawal from circulation and publicity → sealing of premises → forfeiture. Understanding the full chain helps management appreciate that each stage compounds the losses of the previous one, and that early cooperation with the agency is always cheaper than contested enforcement.

Insight five: five of the six grounds are within the company’s own control.

Grounds (a) truthfulness of information, (b) compliance with conditions, (c) quality, performance and safety, (e) premises compliance, and (f) proactive notification — five of them depend on the company’s internal management. Only (d), ineffectiveness for the approved purpose, depends more on real-world post-market data, and that ground is precisely the counterpart of the PMS obligations in Article 12: only a solid PMS system can detect a ground (d) risk early and allow proactive handling. The compliance architecture of the whole regulation assumes that companies prevent grounds (a) through (f) before NAFDAC ever has to act.

4. Practical recommendations

  1. Run a retrospective truthfulness check of application information, focusing on classification rationale, manufacturer information, the CMFS, label artwork and performance data.
  2. Bring local partners’ warehousing and distribution premises into the audit scope (GDP / GWP); do not audit documents only.
  3. Build a suspension-trigger self-check list, scoring all six grounds monthly and keeping records.
  4. Handle ground (d) (ineffectiveness) risks proactively; voluntary suspension (Article 8(1)(f)) is preferable to passive enforcement action.
  5. Prepare a withdrawal-from-circulation contingency plan: channel notification templates, stock reconciliation procedures, and agreed public-communication lines.
  6. Plan the resumption path in advance: notification plus the renewal fee where the certificate has expired (Article 8(3)).

5. Verification checklist

  • □ A retrospective truthfulness check of application information has been completed (Article 8(1)(a)).
  • □ The list of registration conditions is known and internal compliance records exist (Article 8(1)(b)).
  • □ Evidence of quality, performance and safety compliance is on file (Article 8(1)(c)).
  • □ Post-market effectiveness data is collected through PMS with evaluation records (Article 8(1)(d)).
  • □ Manufacturing, warehousing and distribution premises have been audited against GMP / GDP / GWP (Article 8(1)(e)).
  • □ A withdrawal-from-circulation contingency plan has been drawn up and rehearsed.
  • □ The resumption path (notification, renewal fee) has been clarified (Article 8(3)).

Regulatory information verified as of 29 October 2026. All citations have been checked against the official NAFDAC Regulations text (S.I. No. 42 of 2024, Articles 8(1)–(3), 15, 48, 49), the GMP Guidelines (DER-GDL-025-00 §11.3–§11.7) and R&R-GDL-008-02 (§5.0–§5.1, §12.2).

  • Local resources in Nigeria: GRZAN can coordinate locally licensed importer and authorised representative resources, covering NAPAMS electronic submission, dossier screening permit coordination, import permits, sample delivery and laboratory analysis support.
  • Service capabilities: classification determination, registration pathway selection, technical documentation (IMDRF ToC), CMFS and legalisation, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, change management and renewal.
  • Contact: hito.lin@grzan.cn; website www.grzan.cn; email info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail